Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

PURPOSE: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cohen, Ezra E.W., Haraf, Daniel J., Kunnavakkam, Rangesh, Stenson, Kerstin M., Blair, Elizabeth A., Brockstein, Bruce, Lester, Eric P., Salama, Joseph K., Dekker, Allison, Williams, Rosalyn, Witt, Mary Ellyn, Grushko, Tatyana A., Dignam, James J., Lingen, Mark W., Olopade, Olufunmilayo I., Vokes, Everett E.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903330/
https://ncbi.nlm.nih.gov/pubmed/20498391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.0397
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items